Press coverage about Sientra (NASDAQ:SIEN) has trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sientra earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 45.8013992867472 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Several equities analysts have recently weighed in on SIEN shares. William Blair upgraded shares of Sientra from a “market perform” rating to an “outperform” rating in a research report on Wednesday, September 13th. ValuEngine upgraded shares of Sientra from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Lake Street Capital restated a “buy” rating and set a $15.00 price objective (up previously from $11.00) on shares of Sientra in a research report on Wednesday, August 2nd. Canaccord Genuity started coverage on shares of Sientra in a research report on Monday, August 28th. They set a “buy” rating and a $14.00 price objective for the company. Finally, Stephens started coverage on shares of Sientra in a research report on Tuesday, July 11th. They set an “overweight” rating and a $12.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $13.67.

Shares of Sientra (NASDAQ SIEN) opened at 14.70 on Monday. Sientra has a 1-year low of $6.92 and a 1-year high of $16.49. The stock’s market capitalization is $283.80 million. The firm’s 50-day moving average is $11.65 and its 200-day moving average is $9.52.

Sientra (NASDAQ:SIEN) last issued its quarterly earnings data on Wednesday, August 9th. The medical instruments supplier reported ($0.55) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.04. Sientra had a negative return on equity of 52.30% and a negative net margin of 173.83%. The business had revenue of $8.20 million during the quarter, compared to analyst estimates of $6.97 million. Sientra’s quarterly revenue was up 32.3% compared to the same quarter last year. On average, analysts predict that Sientra will post ($2.94) earnings per share for the current fiscal year.

WARNING: “Sientra (SIEN) Receiving Somewhat Positive Media Coverage, Study Finds” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at

About Sientra

Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.

Insider Buying and Selling by Quarter for Sientra (NASDAQ:SIEN)

Receive News & Stock Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related stocks with our FREE daily email newsletter.